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Abstract
Background: Chlamydia trachomatis is responsible for trachoma, the primary cause of preventable blindness worldwide.
Plans to eradicate trachoma using the World Health Organization’s SAFE program (Surgery, Antibiotics, Facial Cleanliness
and Environment Improvement) have resulted in recurrence of infection and disease following cessation of treatment in
many endemic countries, suggesting the need for a vaccine to control infection and trachomatous disease. Vaccine
development requires, in part, knowledge of the mucosal host immune responses in both healthy and trachomatous
conjuctivae—an area of research that remains insufficiently studied.
Methodology/Principal Findings: We characterized 25 secreted cytokines and chemokines from the conjunctival mucosa of
individuals residing in a trachoma endemic region of Nepal using Luminex X100 multiplexing technology.
Immunomodulating effects of concurrent C. trachomatis infection were also examined. We found that proinflammatory
cytokines IL-1b (r=0.259, P=0.001) and TNFa (r=0.168, P,0.05) were significantly associated with trachomatous disease
and concurrent C. trachomatis infection compared with age and sex matched controls from the same region who did not
have trachoma. In support of these findings, anti-inflammatory cytokine IL-1 receptor antagonist (IL-1Ra) was negatively
associated with chronic scarring trachoma (r=20.249, P=0.001). Additional cytokines (Th1, IL-12p40 [r=20.212, P,0.01],
and Th2, IL-4 and IL-13 [r=20.165 and 20.189, respectively, P,0.05 for both]) were negatively associated with chronic
scarring trachoma, suggesting a protective role. Conversely, a pathogenic role for the Th3/Tr1 cytokine IL-10 (r=0.180,
P,0.05) was evident with increased levels for all trachoma grades. New risk factors for chronic scarring trachoma included
IL-6 and IL-15 (r=0.259 and 0.292, respectively, P,0.005 for both) with increased levels for concurrent C. trachomatis
infections (r=0.206, P,0.05, and r=0.304, P,0.005, respectively). Chemokine protein levels for CCL11 (Eotaxin), CXCL8 (IL-
8), CXCL9 (MIG), and CCL2 (MCP-1) were elevated in chronic scarring trachoma compared with age and sex matched
controls (P,0.05, for all).
Conclusions/Significance: Our quantitative detection of previously uncharacterized and partially characterized cytokines, a
soluble cytokine receptor,andchemokinesforeach trachomagradeandassociationswith C.trachomatis infectionsprovide, to
date, the most comprehensive immunologic evaluation of trachoma.These findings highlight novel pathologic and protective
factors involved in trachomatous disease, which will aid in designing immunomodulating therapeutics and a vaccine.
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Introduction
Trachoma, the leading global cause of preventable blindness,
has plagued populations for thousands of years [1]. There are over
360 million trachoma cases of whom ,6 million are blind [2,3].
Limited access to clean water and inadequate sanitary conditions
provides ideal conditions for the persistence of this endemic disease
caused by the obligate intracellular bacterium Chlamydia trachomatis.
Additionally, C. trachomatis is the leading bacterial cause of sexually
transmitted diseases (STD) throughout the world [4], causing
chronic conditions such as arthritis [5], infertility and ectopic
pregnancy [6]. The economics and health burden from trachoma
alone claims billions of dollars in productivity loss in already
poverty stricken countries [7]. Recognizing this, the World Health
Organization (WHO) proposed the SAFE program (Surgery,
Antibiotics, Facial cleanliness and Environmental improvement) in
2001 with the goal of eradicating blinding trachoma by the year
2020.
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with repeated C. trachomatis infections of the conjunctivae, which
can eventually lead to scarring and blindness from trachomatous
trichiasis (TT; $1 in-turned eyelash) [1]. Recently, we and others
have demonstrated that the S and A components of the SAFE
program results in recurrent C. trachomatis infections and disease in
endemic countries 6–24 months following cessation of treatment
[8,9,10,11,12,13]. Additionally, the difficulty in implementing and
sustaining the F and E programs in resource poor countries
suggests that a vaccine is the most effective method of control.
Designing efficacious vaccine candidates requires, in part,
characterization of host inflammatory risk factors versus protective
immunological components that are associated with the different
grades of trachoma. These include follicular trachomatous
inflammation (TF); intense trachomatous inflammation (TI);
trachomatous conjunctival scarring (TS), trachomatous trichiasis
(TT) and corneal opacity (CO) [14]. A limited number of animal
models and human studies have begun to elucidate the host
immune response in trachoma. The use of Giemsa stains and
immunohistochemistry has characterized active trachoma (TF, TI
or both) in young children as an epithelial and stromal infiltrate
containing neutrophils [15], macrophages, dendritic cells, and B
and T lymphocytes [16]. Physiologic characterization has been
obtained from non-human primate models where trachoma-
induced immunopathology consisted of conjunctival follicles
containing B cells coexisting with a rich T lymphocyte population
in the perifollicular area [17,18]. These T lymphocytes were
associated with macrophages, and epithelial and stromal cells. The
quantity and size of trachoma-related follicles have been shown to
directly correlate with the frequency of repeated C. trachomatis
infections in the non-human primate model [17].
Characterization of intense inflammation during early stages of
trachomatous disease exhibits elevated transcriptional levels of the
proinflammatory cytokines TNFa and IL-1b, and amplified
expression in the presence of C. trachomatis infection in human
populations [19,20,21]. These studies also linked elevated Th1
cytokines IL-12 and IFNc mRNA levels in conjunctival samples
with TI cases [19,20,21,22] and diminished levels in the presence
of scarring [19]. No mRNA expression was detected for the Th2
cytokines IL-4 and IL-5 for any trachoma grade [19,21].
However, elevated IL-10 mRNA levels were apparent in TF and
TI cases who were also infected with C. trachomatis [21,22].
Together these data suggest Th1 polarization as protective and IL-
10 as a risk factor for exacerbating disease progression.
As trachomatous scarring develops, there is a diminished
lymphocytic proliferative response to C. trachomatis elementary
bodies (EBs) in both cynologus monkeys [23] and humans [24,25].
Significantly elevated levels of T cytotoxic/suppressor cells
compared to helper T lymphocytes have been shown in monkeys
with chronic ocular infections [17,23,26]. Similarly, this immu-
nosuppressive polarized environment was mirrored in infected TS
cases where conjunctival IFNc, TNFa, and IL-12 mRNA
expression levels were decreased compared to levels among TF/
TI cases, although IL-1b and TGFb1 levels were consistently
elevated for all grades of trachoma [19]. However, these studies
have not examined the post-transcriptional and –translational
regulation of these cytokines and their respective protein levels,
making it difficult to assess their relevance to trachoma
[27,28,29,30]. To date, only one study has evaluated protein
levels in which TS cases were shown to have significantly elevated
TNFa levels compared with controls [31].
While the above data have started to elucidate our understand-
ing of the immune responses in trachoma, the lack of cytokine
protein data prevent us from determining the immunological
modulators associated with successive disease severity and
identifying protective versus pathologic risk factors. Furthermore,
resolving infection and disease relies on localizing and attracting
effective leukocyte populations to the infected site. Chemokines are
a group of small molecular weight proteins (8–12 kDa) responsible
for such a task. However, there have been no studies of
chemokines and their association with trachoma. To begin to
address these deficiencies, we quantitatively analyzed 25 secreted
conjunctival mucosal cytokine and chemokine proteins in a
trachoma endemic Nepali population. We detected previously
uncharacterized and partially characterized cytokines, a soluble
cytokine receptor, and chemokines for each grade of trachoma,
and the effect of C. trachomatis infections on their production. Our
data provide the most comprehensive immunological evaluation
associated with trachoma to date.
Methods
Study population, trachoma grading, and ethics
This cross-sectional study included 208 individuals residing in a
trachoma endemic region of Southwestern Nepal that were age
and sex matched post hoc using a stratified sampling method.
Samples from mutually exclusive trachoma grades (TF/TI, TS,
TT, and Normal) were placed into separate strata by age (5 year
spread) and sex. Samples were randomly selected (using a table of
random numbers) from each age and gender stratum for each
trachoma grade and matched with randomly selected samples
from each age and gender stratum for normals. Verbal informed
consent was obtained from all study subjects following the
institutional review board approval by Children’s Hospital and
Research Center at Oakland, CA, and the Nepal Netra Jhoti
Shang. Verbal consent was documented on an information sheet
by the team member who consented each individual who agreed
Author Summary
Trachoma, a disease of antiquity dating back to the 16th
century B.C.E., predominates among developing countries,
where it remains the primary cause of preventable
blindness worldwide. In trachoma, recurrent Chlamydia
trachomatis bacterial infections during childhood are
thought to result in inflammation and subsequent
conjunctival scarring that can progress to trichiasis (TT;
chronic trachoma; inversion of $1 eyelash that touches
the globe of the eye). The trachomatous follicular grade
(TF; active disease) is a self-limiting disease, suggesting the
coexistence of protective inflammatory proteins. The
trachomatous inflammatory grade (TI; active disease) is
more likely to progress to trachomatous scarring (TS;
chronic trachoma). To date, there are only a handful of
studies that have examined the immune response in
trachoma, and these were primarily based on gene
expression. Characterizing quantified conjunctival mucosal
immune differences for secreted proteins among individ-
uals with no, active, and chronic trachoma may identify
protein biomarkers associated with protection versus
disease, which would greatly aid our understanding of
the immunopathogenesis of trachoma. In this study, we
characterized 25 cytokine and chemokine proteins for all
trachoma grades. We identified eight cytokines and
chemokines as risk factors for chronic trachoma and four
as protective. Together, these findings further characterize
the immunopathologic responses involved during tracho-
ma, which will likely aid in the design of a vaccine and
immunomodulating therapeutics for trachoma.
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subject was performed according to a modified grading scale
previously described by WHO [14]. Briefly, the grades were: no
evidence of trachoma characterized by #4 follicles on the lower 2/
3 of the upper tarsal conjunctiva (Normal denoted as T0), follicular
and/or intense trachomatous inflammation (TF/TI), trachoma-
tous conjunctival scarring (TS), trachomatous trichiasis (TT) and
TT with inflammation (TT/TI). An agreement between two of
three independent readers (authors DD and RK, and Dr. Tracey
Hessel) on final grading was made for each patient.
Sample collection
Conjunctival mucosal secretions were obtained by applying a
sterile Weck-cel sponge (Medtronic Inc., Minneapolis, MN) to the
inner canthus of each eye and allowing the swab to reach
saturation. Samples were placed in a sterile eppendorf tube. A
Dacron swab (Remel Inc., Lenexa, KS) was used to sample the
upper tarsal and lower conjunctivae of each eye and was placed in
M4-RT media (Micro Test Inc., Lilburn, GA) immediately
following collection. All swabs were kept on ice for no longer
than eight hours until transfer to liquid nitrogen tanks and then to
Children’s Hospital Oakland Research Institute, Oakland, CA
and stored at 280uC until analyzed.
Detection of C. trachomatis in conjunctival samples
DNA was isolated from a M4-RT media containing the
conjunctival swabs as previously described [32] following manufac-
turer’s instructions. Samples were defined as positive at an
OD450 nm.0.8 and negative at an OD450 nm,0.2 [32]. Equivocal
samples were defined as those that fell within an OD450 nm of 0.2 to
0.8, and were further evaluated using an in-house validation PCR test
to assess the presence or absence of chlamydiae as we have described
previously [10]. Briefly, DNA from equivocal and negative and
positive control samples were amplified using primers flanking the
ompA gene. The presence of a 1200 bp band corresponding to the
positive C. trachomatis DNA control, while the negative control was
negative, defined an equivocal sample as positive for C. trachomatis.
Detection of cytokine and chemokine protein levels in
conjunctival mucosal samples
Mucosal sponges were thawed on ice, and 80 ml of resuspension
fluid [50 mM Tris, 0.15 M NaCl, 10 mM CaCl2, serine and
cysteine protease inhibitors (Protease Inhibitor Cocktail tablets,
Roche Diagnostics, Mannheim, Germany) at pH 7.5] was applied
to each sponge. Fluid was extracted, and insoluble protein
separated via centrifugation at 10,0006g for 10 min at 4uC.
Samples were applied to a Human Cytokine/Chemokine 25-
plex [IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-10, IL-
12p40, IL-13, IL-15, IL-17, IFNa, IFNc, TNFa, GM-CSF, CCL2
(MCP-1), CCL3 (MIP-1a), CCL4 (MIP-1b), CCL11 (Eotaxin),
CXCL10 (IP-10), CXCL9 (MIG), CCL5 (RANTES), IL-1Ra, and
IL-2R] 96 well plate assay (Biosource International, Inc.,
Camarillo, CA) following manufacturer’s instructions. Briefly,
25-Plex beads were vortexed and sonicated to disperse aggregates,
and washed using a vacuum manifold not exceeding 5 psi.
Subsequently, 25-Plex beads were incubated with 50 ml of sample
or standards for 2 h on an orbital shaker at 500 rpm. Wells were
aspirated and washed as described above through the vacuum
manifold. Biotinylated detector antibodies were added and
incubated on the orbital shaker for 1 h with subsequent washes.
After the addition of Streptavidin-RPE, the plates were analyzed
using a Luminex X100 instrument (Luminex Technologies, Inc) to
determine the quantities of each protein. Calibration was
performed before each run, and all 25 cytokines/chemokines
were gated (9050–12050) to eliminate bead aggregates and debris
associated with the samples. Luminex analysis was set to 50 ml/
sample and 80 events/bead. Standard curves were assessed from
duplicates consisting of all 25 cytokines/chemokines using a five
parameter logistic modeling system. Contiguous dilutions (8 three-
fold followed by 3 two-fold dilutions) were applied to the
standards, and resuspension fluid was used to determine
background. Sensitivity levels were determined for each cyto-
kine/chemokine as the lowest dilution, two standard deviations
above background. Sensitivity levels were as follows: TNFa
(0.2 pg/ml), IL-1b (1.9 pg/ml), IL-1Ra (14–31560 pg/ml), IL-6
(2.6 pg/ml), IL-4 (1.0 pg/ml), IL-5 (0.8 pg/ml), IL-13 (2.3 pg/ml),
IL-12p40 (2.2 pg/ml), IFNc (0.9 pg/ml), IL-10 (0.3 pg/ml), IL-2
(0.9 pg/ml), IL-2R (4.5 pg/ml), IL-15 (2.1 pg/ml), IFNa (4.2 pg/
ml), IL-7 (16.2 pg/ml), IL-17 (5.6 pg/ml), Eotaxin (0.3 pg/ml),
GM-CSF (2.7 pg/ml), IL-8 (2.7 pg/ml), MCP-1 (12.0 pg/ml),
MIG (9.9 pg/ml), IP-10 (4.0 pg/ml), MIP-1a (4.3 pg/ml), MIP-
1b (5.5 pg/ml) and RANTES (8.9 pg/ml).
Statistical analysis
We used a stratified sampling method to divide the population
into mutually exclusive groups based on disease grade (TF/TI vs
T0, TS vs T0, etc) as described above. Cytokine and chemokine
data, comparing particular disease grades versus age and sex
matched controls, were assessed for normality by Shapiro-Wilk W
test to determine the appropriate statistical tests. Two-sample
Wilcoxon rank-sum (Mann-Whitney) test was performed when p
values were ,0.05 from the Shapiro-Wilk test. Student t test with
equal variance was used when p values were .0.05 (Figures 1–4).
Significance for the association between cytokine/chemokine
production and different trachoma grades was determined using
multiple logistic regression and adjusting for age and C. trachomatis
infection for the TF/TI cases. Statistical analysis of immuno-
modulating effects by C. trachomatis for trachoma cases or controls
was determined using frequency of cytokine or chemokine
detection as the dependent variable adjusting for age. We used
Spearman’s rank test to quantify the association between
individual cytokines/chemokines and different trachoma grades
and infection. All statistics were performed using Stata 9.0
software (Stata Corp, College Station, TX).
Results
Clinical and microbiologic characteristics of the study
population
Our Nepali study population comprised individuals with TF/
TI, TS, TT, and TT/TI who were age and sex matched with
identical numbers of individuals without disease (T0) from the
same community (Table 1). We assessed the prevalence of C.
trachomatis infection with different grades of trachoma. Table 1
shows that there was an inverse association between C. trachomatis
infection and age [P=0.003; OR=0.97 (0.95–0.99)] while
infection was directly associated with TF/TI cases [(P=0.017;
OR=4.4 (1.30–14.92)]. The presence of chronic trachoma
defined as any grade demonstrating scarring (TS, TT and TT/
TI) was associated with age [P,0.001; OR=1.20 (1.12–1.30)].
Pro-inflammatory mediators in conjunctival mucosal
secretions are associated with trachomatous
inflammation
Wefound significantly elevated proteinconcentrations ofthe pro-
inflammatorycytokine TNFa for TF/TI cases compared to age and
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inflammatory cytokine IL-1b. For the pleiotropic cytokine IL-6,
which has been linked to acute and chronic inflammation [33], we
found a greater percentage of TF/TI cases (50%) that produced IL-
6 compared with controls (25%) (Table S1).
A previous study suggested a protective effect with elevated Th1,
IL-12 and IFNc, mRNA expression for cases with TF/TI, but not
for those with scarring [19]. At the protein level, we did not find the
same association for TF/TI cases. For Th2 cytokines, we detected
IL-4 and IL13 protein levels in over 60% of TF/TI cases compared
to controls. However, minimal differences in protein concentrations
were observed between the two groups (data not shown). The anti-
inflammatory and Th2 cytokine IL-10, which is also referred to as a
Th3/T regulatory cytokine 1 (Tr1), was significantly associated with
TF/TI cases (Figure 1B, P=0.005) where the mean represented a
three-fold higher concentration compared with controls.
We found no significant elevation in any of the IL-2 family of
cytokines and receptors (IL-2, IL-7, IL-15, and IL-2R) for the TF/
TI cases (Table S1 and data not shown).
We found minimal differences in conjunctival mucosal chemo-
kine protein levels among TF/TI cases except for the CXC family
where significantly elevated levels of IL-8 and MCP-1 were found
among TF/TI cases compared to controls (Figure 1C; P,0.05 and
P,0.005, respectively). These chemokines are primarily associated
with attracting and activating neutrophils, monocytes and T
lymphocytes [34], which have all been linked to the immunopa-
thology associated with TF/TI [15,16].
Elevated pro-inflammatory cytokine and chemokine
proteins in conjunctival mucosal secretions predominate
in trachomatous scarring cases
Cases with scarring had significantly elevated levels of the
proinflammatory cytokines TNFa and IL-1b compared to controls
(Figure 2A, P=0.001 and P,0.05, respectively). Levels of IL-6
were barely detected among these cases. However, there was an
overall greater frequency of detectable IL-6 protein levels among
TS cases (Table S1, 17% TS vs 0% T0), which was similar to the
TF/TI cases mentioned above.
The Th2 cytokine IL-13 was decreased in TS cases compared
with controls (Table S1, P,0.005), while IL-12p40 was elevated
(Figure 2B, P,0.05), suggesting a slight polarization towards the
Figure 1. Elevated concentrations of TNFa, IL-10, IL-8 and MCP-1 predominated in TF/TI conjunctival mucosal secretions.
Concentrations of conjunctival mucosal cytokines and chemokines among individuals residing in a trachoma endemic region of Nepal were analyzed
using multiplexing Luminex technology (see methods). The data are grouped by three categories: (A) proinflammatory cytokines, (B) Th1/Th2/Th3
cytokines and (C) chemokines, representing individual conjunctival mucosal secretory concentrations from TF/TI cases (n=28) and age and sex
matched controls (T0, n=28). Lines designate the geometric means of each group. Statistical differences for cytokine and chemokine concentrations
between cases with TF/TI and controls with T0 were denoted by * P,0.05 or ** P,0.01, Wilcoxon rank-sum test.
doi:10.1371/journal.pntd.0000264.g001
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levels for TS cases, although not quite significant (Figure 2B,
P=0.051), suggested immuno-regulatory patterns coexisting with
Th1. A distinguishing finding for TS cases was the significant
protein elevation of an IL-2 family cytokine, IL-15 (Figure 2C,
P,0.05). This cytokine is produced by a plethora of cell types,
including epithelial, monocytic and dendritic cells, and is involved
in the activation of effector memory T lymphocytes [35].
Significantly elevated levels of Th1 CC chemokines, MIP-1a
and MIP-1b (Figure 2D, P,0.01 and P,0.001 respectively), and
Th2 chemokines, MCP-1 and Eotaxin (Figure 2D, P,0.01) were
found for the TS cases compared with controls.
Elevated IL-6 protein levels in conjunctival mucosal
secretions predominate among trachomatous trichiasis
cases
Conjunctival mucosal secretions demonstrated minimal differ-
ences at the protein level among proinflammatory and Th1, Th2
and Th3 cytokines for TT cases (data not shown). However, IL-6
Figure 2. Multiple inflammatory mediators are elevated among individuals with trachomatous scarring (TS) compared to controls.
Cytokine and chemokine concentrations within conjunctival mucosal secretions from Nepali patients exhibiting TS were compared to age and sex
matched controls. The data are grouped into significant difference within four categories: (A) proinflammatory cytokines, (B) Th1/Th2/Th3 cytokines,
(C) IL-2 cytokine family, and (D) chemokines, representing individual conjunctival mucosal secretory concentrations from TS patients (n=18) and age
and sex matched controls (T0, n=18). Lines designate geometric means of each group. Statistical differences for cytokine and chemokine
concentrations between TS and T0 was denoted * P,0.05, ** P,0.01 and *** P,0.001, Wilcoxon rank-sum test or Student t test when Shapiro-Wilk W
test $0.05.
doi:10.1371/journal.pntd.0000264.g002
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compared to controls (Figure 3A, P,0.01) as in the other
trachoma grades. For the IL-2 family of cytokines, minimal
differences were observed except for significantly elevated
concentrations of IL-15 (Figure 3B, P,0.05), which further
suggests that this cytokine is a risk factor for chronic trachoma.
For chemokines, TT cases had increased MIG protein levels
compared with controls (Figure 3C, P=0.05), which were not
observed in other trachoma grades.
Low levels of conjunctival mucosal IL-12p40 and IL-1Ra
distinguish trachomatous trichiasis with inflammation
cases from controls
To our knowledge, the inflammatory response in TT/TI cases
has been characterized only once for a limited number of cytokine
mRNA expression levels [19]. In our study, the most novel finding
was the significant reduction in IL-1Ra protein for cases with TT/
TI (Figure 4A, P,0.001) compared to controls, further supporting
a chronic inflammatory environment for this grade. This is the first
time an IL-1b antagonist has been characterized in trachomatous
disease. In agreement with an inflammatory environment,
significantly higher protein levels of IL-1b were also evident in
TT/TI cases compared to controls (Figure 4A, P,0.05).
For Th1, Th2 and Th3 cytokines, TT/TI cases had
significantly reduced protein levels for the Th1 cytokine IL-
12p40 (Figure 4B, P,0.001) and for the Th2 cytokine IL-4
(Figure 4B, P,0.05). There was a trend for elevated protein levels
for the Th3/Tr1 cytokine IL-10, similar to what was observed in
most grades of trachoma (Table S1 and data not shown). Among
the IL-2 family, the TT/TI cases had elevated levels of IL-2 and
IL-15 compared to controls (Figure 4C, P,0.05).
In agreement with the decreased Th1 response, CC chemokines
MIP-1a and MIP-1b were significantly lower for TT/TI cases
compared to controls (Table S1, P,0.05 for both). However,
CXC chemokines, IL-8 and MCP-1, remain elevated (Figure 4D,
P,0.05).
Elevated Th1 and Th2 cytokines and IL-1Ra levels in
conjunctival mucosal secretions distinguish
trachomatous inflammation from scarring grades of
trachoma
Figure 5A shows that TF/TI cases had a higher frequency of
TNFa production compared to all other grades, although the
difference was only significant between TF/TI and TT/TI
(P,0.05), likely due to small patient numbers for TS and TT. A
reverse trend was apparent for IL-1b, which was supported by the
significant reduction in its soluble antagonist receptor (IL-1Ra)
concentrations in the TT/TI cases compared with TF/TI and TS
cases (data not shown; P,0.05 and P,0.005 respectively).
Cytokines involved in Th1 and Th2 phenotypes showed a
consistent reduction for all grades (TF/TI to TT/TI) (Figure 5B)
with TF/TI and TS cases demonstrating more frequent IL-4
production over TT/TI and TT cases (Figure 5B, P,0.01,
respectively). This correlated with decreased Th2, IL-13, and
Th1, IFNc and IL-12p40, cytokines for TT/TI cases (Figure 5B;
P,0.05; IL-12p40: OR=0.80 (0.66–0.97), P,0.05 TT/TI versus
TS). Among the IL-2 family of cytokines and receptor, decreased
IL-2R levels were evident in TT/TI cases compared with TF/TI
cases, although these differences were not significant (P=0.082,
data not shown). However, these data correlated with elevated IL-2
production in TT/TI compared to TF/TI cases (Table S1), further
supporting IL-2 as a risk factor for the development of TT/TI.
A significant reduction in IP-10 levels was found for TT/TI
cases compared with TF/TI cases (OR=0.9980 (0.9961–0.9998),
P,0.05). Though not significant, a reverse trend was found for
MCP-1 levels.
Elevated protein levels of chemokines, pro-inflammatory
and Th3/Tr1 cytokines and lower levels of Th1 and Th2
cytokines in conjunctival mucosal secretions
characterized chronic trachoma compared with controls
The effects of chronic trachoma (TS, TT and TT/TI) on
inflammatory components were elucidated by grouping these
grades and comparing them against their age and sex matched
controls. Inflammatory patterns for cases with chronic trachoma
compared with controls are shown in Table 2 and Table S2;
significantly elevated TNFa, IL-1b and IL-6 concentrations and
diminished concentrations of the anti-inflammatory cytokine IL-
1Ra were found in chronic trachoma cases compared with
controls.
In characterizing host Th1, Th2 and Th3 cytokine levels, IL-4,
IL-13 and IL-12p40 were negatively associated with chronic
trachoma cases compared with controls (Table 2). However,
elevated IL-10 levels were associated with chronic cases (Table 2),
further supporting an association with the Th3/Tr1 phenotype
and the role of IL-10 as a risk factor for chronic trachoma.
Members of the IL-2 cytokine family, IL-2 and IL-15, were also
significantly associated with chronic trachoma cases compared
with controls (Table 2).
Figure 3. Trichiasis patients have elevated IL-6 and IL-15 levels compared to controls. Cytokine and chemokine concentrations within
conjunctival mucosal secretions from Nepali patients exhibiting TT were compared to age and sex matched controls. The data are grouped into
significant difference within three categories: (A) proinflammatory cytokines, (B) IL-2 cytokine family and (C) chemokines, representing individual
conjunctival mucosal secretory concentrations from TT patients (n=20) and age and sex matched controls (T0, n=20). Lines designate geometric
means of each group. Statistical differences between TT and TO was denoted * P,0.05 or ** P,0.01, Wilcoxon rank-sum test.
doi:10.1371/journal.pntd.0000264.g003
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cantly associated with elevated levels of Eotaxin, IL-8, MCP-1 and
MIG compared with controls (Table 2).
Influence of C. trachomatis infections on cytokine,
cytokine receptor and chemokine protein levels in
conjunctival mucosal secretions for all grades of
trachoma
Table 3 shows the frequency of cytokine, chemokine and
cytokine receptor protein concentrations comparing C. trachomatis
infected and uninfected patients for trachoma cases (all grades) and
for controls. TNFa and IL-6 were significantly associated with C.
trachomatis infections for chronic trachoma cases (Table 3 and S3)
with similar patterns for IL-1b, though not significant (Table S3
and S4). This phenotype was not evident among controls (Table 3).
Minimal differences were observed for Th1 and Th2 cytokines
in the presence or absence of C. trachomatis infections (Table S3 and
S4). However, elevated IL-10 levels persisted in the presence of C.
trachomatis infections regardless of trachoma grade (Table 3).
Additionally, C. trachomatis infections appeared to effect the IL-2
family of cytokines with a significant association of elevated IL-2
concentrations with controls (Table 3); elevated IL-15 was
associated with trachoma (Table 3 and Table S3).
In the chemokine family, C. trachomatis infection was associated
with increased levels of Th1-associated chemokines MIP-1b and
RANTES (Table 3). Independent of trachoma grade, MIG was
significantly associated with infection (OR=2.61 (1.25 to 5.45),
P=0.011).
Discussion
While there is some important research on cytokine mRNA
expression in association with trachoma, our fundamental
knowledge of the host immune response has been limited by a
lack of quantitative protein data, especially for those cytokines and
chemokines that are post-transcriptionally and –translationally
modified, in association with each grade of trachoma. The goal of
this study was to validate previous gene expression findings and to
characterize novel inflammatory cytokine and chemokine protein
concentrations in mucosal conjunctival secretions and how each
may influence inflammation for the different grades of trachoma-
tous disease. Additionally, we further characterized immuno-
regulatory effects induced by concurrent C. trachomatis infection.
Our Nepali study population showed a significant inverse
association of C. trachomatis infection with age and a direct
association with TF/TI cases agreeing with our previous findings
and those of others [19,22,32].
Proinflammatory cytokines have previously been associated with
acute and chronic trachoma [36,37]. We and others [19,20] found
elevated TNFa levels among TI and chronic trachoma cases and
also higher levels when both C. trachomatis infection and trachoma
were present. Additionally, in our study, elevated IL-1b levels were
significantly associated with chronic trachoma cases but not with
infection. Previous studies have demonstrated elevated IL-1b
mRNA levels during both disease and infection [19,20]. These
differences may be due to post-translational modifications of IL-
1b, thus supporting both findings but suggesting the need for
quantitative protein studies for confirmation. The previous
associations of these cytokines with the induction of scarring-
associated proteins, matrix metalloproteins (MMPs) and collagen
[19,20,21], suggest plausible mechanisms for the development and
progression of chronic trachoma. This chronic inflammatory
phenotype is further supported in our study by the significantly
decreased levels of the anti-inflammatory cytokine IL-1Ra.
Recently, Hvid et al. characterized the role of IL-1Ra and IL-1a
in a human fallopian tube organ culture model [38]. C. trachomatis
infection resulted in destruction of ciliated and secretory cells
within the tubes. However, when co-cultured with IL-1Ra, tissue
destruction was minimal while IL-1a exacerbated disease
pathology. In trachoma, the prolonged production of TNFa and
IL-b together with a reduction in IL-1Ra inhibitory pathways may
promote the development of scarring and progression to TT.
The pleiotropic cytokine IL-6 has been associated with chronic
trachoma [33]. One previous study evaluated IL-6 gene expression
in trachoma but the findings were inconclusive due to detectable
mRNA levels in only two patients [19]. We found elevated IL-6
production for all grades of trachoma. Additionally, we demon-
strated for the first time a significant association of C. trachomatis
infection with elevated IL-6 protein levels in both inflammatory
Table 1. Characteristics of the Nepali population by age, gender, trachoma grades and C. trachomatis infection.
Grade of Disease Total
T0 TI T0 TS T0 TT T0 TT/TI
Age in years [Median
(range)]
A,B
16.5 (3–40) 16.9 (5–40) 37.5 (16–70) 39.7 (16–70) 46.4 (16–70) 48.9 (18–75) 40.0 (13–75) 42.6 (13–75) 35.4
Male 12 12 8 8 9 9 14 14 86
Female 16 16 10 10 11 11 24 24 122
C. trachomatis infection 5/27 14/28
c 4/18 3/18 0/20 5/20 2/37 5/38 38/208
AAge was significantly associated with chronic trachoma (TS, TT, TT/TI) [P,0.001, OR=1.20 (95% CI, 1.12–1.30)].
BAge was inversely significantly associated with C. trachomatis infection [P=0.003; OR=0.97 (95% CI, 0.95–0.99)].
CSignificant association of TI with active C. trachomatis infection compared to age and sex matched controls with T0 [P=0.017; OR=4.4 (95% CI, 1.30–14.92)].
doi:10.1371/journal.pntd.0000264.t001
Figure 4. Persistent IL-1b elevation with significantly diminished IL-1Ra and IL-12p40 levels distinguish TT/TI from controls. Cytokine
and chemokine concentrations within conjunctival mucosal secretions from Nepali patients exhibiting TT/TI were compared to age and sex matched
controls. The data are grouped into four categories with significant differences: (A) proinflammatory cytokines, (B) Th1/Th2/Th3, (C) IL-2 cytokine
family, and (D) chemokines, representing individual conjunctival mucosal secretory concentrations from TT/TI patients (n=38) and age and sex
matched controls (T0, n=38). Lines designate geometric means of each group. Statistical differences between TT/TI and T0 was denoted * P,0.05, **
P,0.01 and *** P,0.001, Wilcoxon rank-sum test.
doi:10.1371/journal.pntd.0000264.g004
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study demonstrating elevated IL-6 production in the fallopian
tubes of macaques after repeated infection with C. trachomatis [39].
Murine studies, however, have provided conflicting data. One
study showed an increased bacterial burden and mortality
associated with pulmonary infection with the mouse pneumonitis
strain (MoPn; now referred to as Chlamydia muridarum) in IL-6 -/-
KO mice [40]. In the mouse genital tract model, however, there
was an absence of any pathological or bacterial complications
when IL-6 -/- KO mice were infected with C. muridarum [41].
Darville et al., found that TLR2 -/- KO mice exhibited decreased
levels of IL-6 and oviduct pathology during C. muridarum -genital
tract infection [42], further supporting IL-6 as a risk factor for
chronic trachoma.
Considering the obligate intracellular nature of C. trachomatis
and previous studies, host cell-mediated immunity (Th1) appears
to be critical in eliciting protection against Chlamydia-associated
diseases. Transcriptional studies have associated elevated Th1
cytokines, IL-12 and IFNc, mRNA expression with C. trachomatis
infection for cases with TF/TI [19,21] but decreased levels with
scarring [19]. Wang et al. demonstrated elevated endocervical IL-
12 protein concentrations in adolescents prior to resolution of their
C. trachomatis infection [43], further supporting a role for IL-12 in
host defense against infection. In our study, we found minimal
differences in IL-12p40 concentrations for TF/TI compared with
controls but significantly decreased mucosal levels associated with
scarring. Additionally, TT/TI cases had lower levels for both Th1
cytokines, IFNc and IL-12p40, compared to TF/TI. Together,
these data suggest that Th1 cytokines are protective immunologic
factors against disease progression. While Th2 cytokines are
known to be associated with humoral mediated immunity,
previous studies have been inconclusive due to undetectable
transcriptional levels of these cytokines [19,21]. In our study, the
Th2 cytokines, IL-4 and IL-13, displayed similar patterns to the
Th1 cytokines, suggesting that both Th1 and Th2 cytokines may
be protective factors against chronic sequelae.
The negative associations of Th1 and Th2 cytokines with
chronic trachoma suggest a potential role for Th3/Tr1. The
previous categorization of IL-10 as an anti-inflammatory Th2
cytokine has recently been extended given the documented
association with T-regulatory (Tregs) cells [44]. Kinjyo et al.
characterized IL-10 as a Th3/Tr1 cytokine, showing the over
Table 2. Association of cytokine and chemokine conjunctival
mucosal protein production with chronic scarring trachoma.
Cytokine/Chemokine Spearman Coefficient
A P-value
Proinflammatory cytokines
TNFa 0.168 0.038
IL-1b 0.259 0.001
IL-1Ra 20.249 0.001
IL-6 0.259 0.001
Th1/Th2/Th3 cytokines
IL-4 20.165 0.041
IL-13 20.189 0.019
IL-12p40 20.212 0.008
IL-10 0.198 0.014
IL-2 family
IL-2 0.249 0.006
IL-15 0.292 0.003
Chemokines
Eotaxin 0.161 0.046
IL-8 0.179 0.026
MCP-1 0.275 0.006
MIG 0.275 0.006
MIP-1a 0.142 0.080
AData represent association of cytokines/chemokines concentrations with
chronic scarring trachoma (TS, TT and TT/TI) compared with age and sex
matched controls. Significant differences were determined using Spearman’s
rank correlation test.
doi:10.1371/journal.pntd.0000264.t002
Figure 5. Immuno-regulatory patterns of cytokines and chemokines exist among chronic trachoma cases versus acute TF/TI cases.
(A) The TF/TI cases had significantly elevated TNFa mucosal protein production compared to the TT/TI cases (P,0.05) and higher IL-6 mucosal
production than TS (P,0.05). (B) TF/TI cases had significantly elevated production of IL-4 compared to TT/TI cases (P,0.01). Further, IL-4 production
was detected more frequently for TS cases compared to TT (P,0.01) and TT/TI cases (P,0.01). Diminished IL-13 production was evident for TT/TI
cases compared to TF/TI cases (P=0.005). TF/TI cases had a significantly higher production of IFNc compared to TT/TI cases (P,0.05). Ratios were
determined by dividing cases with detectable levels of cytokines and chemokines by the total number of cases in each group. Statistics were based
on multiple logistic regression adjusting for C. trachomatis infection, age and sex.
doi:10.1371/journal.pntd.0000264.g005
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gene, SOC3, the suppressor of cytokine signaling [45]. Recently,
Faal et al. found elevated levels of a T cell regulatory gene,
forkhead box 3 (FOXP3), during active trachoma (TF/TI) [22].
This was associated with elevated IL-10 and indoleamine-2, 3-
dioxygenase (IDO) mRNA expression levels. IDO levels have been
associated with immune tolerance and regulatory pathways [46],
which have lead to outgrowth of secondary pneumococcal
infections [47]. Additionally, Mark et al. demonstrated diminished
FOXP3 and IL-10 levels with early clearing of C. trachomatis
infection in a murine model [48]. In our study, IL-10 was
overproduced during all grades of trachoma and with C. trachomatis
infection. These findings are supported by previous IL-10 studies
where elevated mRNA expression was similarly associated with
trachoma and infection [20,21,22]. In the genital tract, elevated
levels of IL-10 have been found in infertile women with
documented C. trachomatis infections [49] and in macaques that
were repeatedly infected with C. trachomatis [39]. These collective
data support the association of IL-10 with a Th3/Tr1 phenotype
and suggest that IL-10 may be a major risk factor for chronic
trachoma associated with C. trachomatis infection. In contrast, Hvid
et al. demonstrated reduced ex vivo fallopian tube pathology with C.
trachomatis infection in the presence of excess IL-10, suggesting a
protective effect [38] at least during the early stages of infection in
the female genital tract. Further investigations are needed to
clearly define the role of IL-10 for each trachoma grade.
The involvement of T lymphocytes in the perifollicular area of
conjunctival follicles suggests an active involvement of the IL-2
family of cytokines, IL-2, IL-2R, and IL-15, in trachoma. Our IL-
2 findings showed an association with chronic trachoma and also
agree with a previous study that found an association of IL-2
mRNA expression, although at low levels, with TI and C.
trachomatis infection [19]. In this study, we demonstrated higher
concentrations of IL-15 in cases with scarring and in cases with
concurrent C. trachomatis infection. IL-15 shares the IL-2Rb and
IL-2Rc receptors with IL-2, and, therefore, has overlapping
bioactivity, which includes the stimulation of proliferation of
activated T cells and natural killer (NK) cells [50,51]. Similar
trends in elevated IL-15 protein have been found in the lymph
nodes of chronically infected HIV patients [52]. In a murine
model, IL-15 KO mice have been shown to have significantly
diminished acute and chronic colitis compared to wild-type mice
[53], further suggesting that IL-15 production is required to
sustain chronic infections. Previous studies have also shown
elevated IL-15 mRNA expression in patients with C. trachomatis-
induced arthritis compared to healthy controls [54]. Immunopa-
thology studies in cynologus monkeys have demonstrated elevated
ratios of CD8+ to CD4+ T cell populations in C. trachomatis
infected naı ¨ve compared to orally immunized monkeys [55],
suggesting that an over abundance of CD8+ T cells are a risk
factor for disease. Recently, IL-15 was linked to extended CD8+
memory T lymphocyte survival rates in mice [56]. IL-15 has also
been associated with Treg proliferation [57]. These data support
IL-2 and IL-15 as risk factors for chronic trachoma, especially with
concurrent C. trachomatis infection, which may be associated with
abundant CD8+ T lymphocyte populations.
Cellular infiltration resulting in typical trachomatous follicles
suggests a major role for chemokines in the progression of disease.
However, to our knowledge, there has been no characterization of
these proteins in trachoma. Most chlamydial studies that have
evaluated chemokines focused on murine and human genital tract
infections. In our study, the significant elevation of CXC
chemokine IL-8 protein levels for all trachoma grades agrees with
previous findings where an abundance of neutrophil populations
were present in conjunctival swabs from individuals with trachoma
[15]. A chlamydicidal role for neutrophils within the conjunctiva
has been demonstrated in one in vitro study by Yong et al. [58].
However, further studies are needed to characterize these findings
in vivo. Our findings for IL-8 are also supported by a murine study
where the murine form of IL-8, MIP-2, had prolonged production
along with neutrophil infiltration and pathology in the genital tract
of BALB/c and C3H/HeN mice but not in the more resistant
C57BL/6 mouse strain [59]. We found pronounced protein levels
for MCP-1 for all grades of trachoma, but lower MIP-1a
Table 3. Association of cytokine and chemokine conjunctival mucosal protein production comparing C. trachomatis infections for
cases with all grades of trachomatous disease and for controls.
No Disease Disease
Cytokine/Chemokine Spearman Coefficient
A P-value Spearman Coefficient
A P-value
Proinflammatory cytokines
TNFa 20.043 0.664 0.298 0.002
IL-6 20.083 0.404 0.206 0.035
Th1/Th2/Th3 cytokines
IFNc 0.153 0.123 0.188 0.055
IL-2 0.286 0.004 0.107 0.280
IL-15 0.096 0.333 0.304 0.002
IL-10 0.223 0.024 0.233 0.017
Chemokines
Eotaxin 20.180 0.069 0.072 0.462
MIG 0.138 0.164 0.181 0.065
MIP-1b 20.115 0.250 0.192 0.050
RANTES 0.012 0.904 0.262 0.007
AData represent the effect of C. trachomatis infection on cytokine and chemokine conjunctival mucosal production for all grades of trachoma (TF/TI, TS, TT and TT/TI) or
age and sex matched controls with no disease. Significance between C. trachomatis infection and no infection was determined using Spearman’s rank correlation test.
doi:10.1371/journal.pntd.0000264.t003
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there was a trend for elevated MCP-1 in TT/TI compared to TS
and TF/TI cases, further associating MCP-1 with chronic grades
of disease. These findings are supported by a murine study that
found elevated MIP-1a and decreased MCP-1 levels among
C57BL/6 mice that had a shorter course of infection [60],
suggesting that these patterns of chemokine production are
protective. Another murine study exhibited elevated levels of
Th1 associated chemokines, RANTES, IP-10 and MIG, with
chronic, upper genital tract infections compared to lower genital
tract infections for C. muridarum [61]. Our study also demonstrated
elevated MIG production among chronic trachoma cases with
elevated RANTES levels among those who were also infected with
C. trachomatis.
In conclusion, we characterized the secreted cytokines,
chemokines, and cytokine receptor associated with immunopa-
thology for each grade of trachoma and determined the
immunomodulating effects of concurrent C. trachomatis infection.
Our studies are in agreement with others who demonstrated Th1
cytokines as protective and Th3/Tr1 cytokine IL-10 as a possible
risk factor for chronic trachoma. Additionally, we reconfirmed
previous gene expression studies linking elevated proinflammatory
cytokines IL-1b and TNFa with C. trachomatis infections, and IL-1b
as a strong risk factor for chronic trachoma. Our findings
expanded on the IL-1b linkage by demonstrating for the first
time, to our knowledge, inverse levels of its antagonist, IL-1Ra, in
association with TT, suggesting that IL-Ra is a protective factor
against chronic sequelae. We also identified two new risk factors,
IL-6 and IL-15, which were associated with chronic trachoma with
significantly elevated levels evident with concurrent C. trachomatis
infection. Currently, we are elucidating signal transduction
pathways affiliated with these cytokines and chemokines during
C. trachomatis infections and their possible inter- and intra-cellular
roles during disease. In addition, future vaccine design will likely
need to take into consideration the immune responses we have
characterized and to ensure a vaccine has the desired protective
outcome.
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